NCT04626635 2026-04-09
COMBINE-EGFR-1
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
Clinical Trials
10 trialsNCT05083481 2026-04-08
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Active not recruiting
NCT06697197 2026-02-03
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT05867420 2026-01-27
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
AskGene Pharma, Inc.
Phase 1/2 Recruiting
NCT06703177 2025-12-03
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT06895928 2025-04-22
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06336707 2024-07-18
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT00861419 2017-02-08
To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.
Amgen
Phase 1 Completed
NCT01055795 2012-12-24
BEL
Duke University
Phase 1 Completed